Bartlett & CO. Wealth Management Trims Abbott Laboratories Holdings

Wealth management firm reduces stake in healthcare product maker by 1.5% in Q4 2025

Apr. 11, 2026 at 7:25am

Got story updates? Submit your updates here. ›

A close-up view of heavy, industrial banking machinery and components, rendered in a high-contrast, cinematic style that emphasizes the physical, mechanical nature of financial services.The intricate inner workings of the financial industry, captured in a dramatic, high-contrast image that evokes a sense of stability and institutional strength.Chicago Today

Bartlett & CO. Wealth Management LLC, a Chicago-based investment firm, reduced its stake in Abbott Laboratories (NYSE: ABT) by 1.5% during the fourth quarter of 2025, according to a recent SEC filing. The firm now owns 1,011,054 shares of the healthcare product maker, valued at approximately $126.7 million.

Why it matters

Abbott Laboratories is a major player in the healthcare industry, known for its diverse portfolio of medical devices, diagnostics, and nutritional products. Tracking institutional investor activity in the stock can provide insights into market sentiment and potential future performance.

The details

In its 13F filing, Bartlett & CO. Wealth Management reported selling 15,032 shares of Abbott Laboratories during the fourth quarter. The firm's total investment in the company now represents approximately 1.7% of its overall portfolio.

  • Bartlett & CO. Wealth Management filed its 13F report for the fourth quarter of 2025 on April 11, 2026.

The players

Bartlett & CO. Wealth Management LLC

A Chicago-based investment management firm that provides wealth management services to individuals and institutions.

Abbott Laboratories

A global healthcare company that develops, manufactures, and markets a broad portfolio of medical products and services, including diagnostics, medical devices, nutritionals, and established pharmaceuticals.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Bartlett & CO. Wealth Management's stake in Abbott Laboratories is a relatively small change, but it could signal a shift in investor sentiment towards the healthcare company. Analysts will likely continue to monitor institutional activity and market trends to assess the long-term outlook for Abbott Laboratories.